XBiotech Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

John Simard

Algemeen directeur

US$5.6m

Totale compensatie

Percentage CEO-salaris	19.2%
Dienstverband CEO	19.7yrs
Eigendom CEO	12.6%
Management gemiddelde ambtstermijn	7yrs
Gemiddelde ambtstermijn bestuur	7.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is John Simard's beloning veranderd ten opzichte van XBiotech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$6m	US$1m	-US$25m
Sep 30 2023	n/a	n/a	-US$23m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	US$5m	US$881k	-US$33m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	n/a	n/a	-US$27m
Mar 31 2022	n/a	n/a	-US$20m
Dec 31 2021	US$8m	US$777k	-US$17m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$3m	US$684k	-US$11m
Sep 30 2020	n/a	n/a	US$677m
Jun 30 2020	n/a	n/a	US$673m
Mar 31 2020	n/a	n/a	US$674m
Dec 31 2019	US$11m	US$591k	US$669m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$1m	US$585k	-US$21m
Sep 30 2018	n/a	n/a	-US$22m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$27m
Dec 31 2017	US$702k	US$566k	-US$33m

CEO

John Simard (62 yo)

19.7yrs

Tenure

US$5,556,481

Compensatie

Mr. John Simard is the Founder of XBiotech, Inc. and serves as its Chairman and has been its Chief Executive Officer and President since March 2005. Mr. Simard serves as the Chairman, Chief Executive Offic...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Simard	Founder	19.7yrs	US$5.56m	12.55% € 29.2m
Angela Hu	Director of Finance	1.8yrs	US$279.29k	0.084% € 194.9k
Sushma Shivaswamy	Chief Scientific Officer	7yrs	US$720.50k	0% € 0

7.0yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Simard	Founder	19.7yrs	US$5.56m	12.55% € 29.2m
W. McKenzie	Independent Director	15.8yrs	US$190.94k	8.66% € 20.1m
Donald MacAdam	Independent Director	6.7yrs	US$187.94k	0.033% € 76.4k
Peter Libby	Member of Scientific Advisory Board & Independent Director	6.2yrs	US$163.94k	0.082% € 191.0k
Alice Gottlieb	Member of Scientific Advisory Board	6.2yrs	geen gegevens	geen gegevens
Alexander Knuth	Member of Scientific Advisory Board	7.6yrs	geen gegevens	geen gegevens
Razelle Kurzrock	Member of Scientific Advisory Board	7.6yrs	geen gegevens	geen gegevens
Andrew Hendifar	Member of Scientific Advisory Board	7.6yrs	geen gegevens	geen gegevens
Jan-Paul Waldin	Lead Independent Director	6.8yrs	US$196.94k	0.66% € 1.5m
Evangelos Giamarellos-Bourboulis	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Mark Rupp	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

7.6yrs

Gemiddelde duur

75yo

XBiotech Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

XBiotech Inc., Annual General Meeting, Jun 20, 2024

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

XBiotech Inc. Announces Executive Changes

Insufficient new directors

XBiotech Inc., Annual General Meeting, Jun 22, 2022

Insufficient new directors

Recent updates

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

XBiotech Inc., Annual General Meeting, Jun 20, 2024

New major risk - Share price stability

Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis

Third quarter 2023 earnings released: US$0.24 loss per share (vs US$0.42 loss in 3Q 2022)

Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke

Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

First half 2023 earnings released: US$0.41 loss per share (vs US$0.56 loss in 1H 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.18 loss in 1Q 2022)

Full year 2022 earnings released: US$1.08 loss per share (vs US$0.58 loss in FY 2021)

XBiotech Inc. Announces Executive Changes

Insufficient new directors

Third quarter 2022 earnings released: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)

XBiotech Inc. Announces First Patient Enrolled into the French National Cancer Institute Sponsored Phase I/Ii/Iii Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.17 loss in 2Q 2021)

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 2000 Dynamic Index

XBiotech Announces Successful Completion of Phase I Portion of Pancreatic Cancer Study

XBiotech Inc., Annual General Meeting, Jun 22, 2022

First quarter 2022 earnings released: US$0.18 loss per share (vs US$0.087 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Insufficient new directors

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.087 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 2Q 2020)

XBiotech Inc. Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

New 90-day high: €17.10

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

New 90-day low: €13.80

Xbiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-Covid-19 Therapeutic Cocktail

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

New 90-day high - €16.04

New 90-day high - €15.29

New 90-day high - €15.07

XBiotech Inc.(NasdaqGS:XBIT) dropped from Russell 3000 Growth Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd